重组人白细胞介素-11联合长春新碱治疗慢性难治性特发性血小板减少性紫癜疗效观察  

Clinical study of recombinant human interleukin-11 combined with vincristine in treating chronic refractory idiopathic thrombocytopenic purpura

作　　者：王琰[1] 刘乃嘉[2] 

机构地区：[1]郑州大学第五附属医院血液肾病内科,河南郑州450052 [2]郑州大学临床医学院,河南郑州450001

出　　处：《中国现代医学杂志》2013年第6期47-49,共3页China Journal of Modern Medicine

摘　　要：目的重组人白细胞介素-11(rhlL-11)联合长春新碱治疗慢性难治性特发性血小板减少性紫癜(ITP)的临床疗效。方法选择40例慢性难治性ITP患者随机分为2组,治疗组采用rhlL-11联合长春新碱治疗,对照组单用长春新碱治疗。结果两组治疗后2周、1个月、3个月血小板计数均有显著差异(P<0.05);根据FAB疗效标准,治疗3个月后治疗组总体有效率75%,显著优于对照组。结论采用rhlL-11联合长春新碱治疗慢性难治性ITP临床疗效满意,无严重副作用,值得推广应用。【Objective】To observe the clinical effect of recombinant human interleukin-11（rhlL-11） combined with vincristine on the treatment of chronic refractory Idiopathic Thrombocytopenic Purpura（ITP）.【Methods】40 patients of chronic refractory ITP were randomly divided into two groups,rhlL-Ⅱ combined with vincristine were given in treatment group,vincristine lonely was given in control group.【Results】 After treatment of 2 weeks,1 month,and 3 months,the platelet counts have a significant difference between two groups.According to the FAB curative effect standard,after treatment of 3 months,the total efficiency rate of treatment group obviously surpasses the control group.【Conclusion】RhlL-11 combined with vincristine is a effective treatment for chronic refractory ITP with few side effects,and was worth popularizing in clinical application.

关 键 词：特发性血小板减少性紫癜 难治性 重组人白细胞介素-11 长春新碱 

分 类 号：R554.6[医药卫生—血液循环系统疾病]